Literature DB >> 8551246

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.

J W Young1, K Inaba.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8551246      PMCID： PMC2192420          DOI： 10.1084/jem.183.1.7

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


× No keyword cloud information.
  48 in total

Review 1.  Toward a genetic analysis of tumor rejection antigens.

Authors:  T Boon
Journal:  Adv Cancer Res       Date:  1992       Impact factor: 6.242

Review 2.  The dendritic cell system and its role in immunogenicity.

Authors:  R M Steinman
Journal:  Annu Rev Immunol       Date:  1991       Impact factor: 28.527

3.  Stimulation with dendritic cells decreases or obviates the CD4+ helper cell requirement in cytotoxic T lymphocyte responses.

Authors:  C J Boog; J Boes; C J Melief
Journal:  Eur J Immunol       Date:  1988-02       Impact factor: 5.532

4.  Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.

Authors:  S Markowicz; E G Engleman
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

5.  Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells.

Authors:  J W Young; R M Steinman
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

6.  Tumor antigen presentation by murine epidermal cells.

Authors:  S Grabbe; S Bruvers; R L Gallo; T L Knisely; R Nazareno; R D Granstein
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

7.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells.

Authors:  P G Coulie; M Somville; F Lehmann; P Hainaut; F Brasseur; R Devos; T Boon
Journal:  Int J Cancer       Date:  1992-01-21       Impact factor: 7.396

8.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.

Authors:  B Gansbacher; K Zier; B Daniels; K Cronin; R Bannerji; E Gilboa
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

9.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

10.  Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ.

Authors:  K Inaba; J P Metlay; M T Crowley; R M Steinman
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307
View more
  45 in total

1.  Expression of MHC and adhesion/costimulation molecules of dendritic cells from human blood during their differentiation in vitro.

Authors:  M Chiriva-Internati; F Grizzi; O Orbetegli; S Lim; P L Hermonat; N Dioguardi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.416

2.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Authors:  C J Kim; T Prevette; J Cormier; W Overwijk; M Roden; N P Restifo; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  1997-07       Impact factor: 4.456

3.  CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion.

Authors:  Silke Gillessen; Yuri N Naumov; Edward E S Nieuwenhuis; Mark A Exley; Frederick S Lee; Nicolas Mach; Andrew D Luster; Richard S Blumberg; Masaru Taniguchi; Steven P Balk; Jack L Strominger; Glenn Dranoff; S Brian Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-07       Impact factor: 11.205

Review 4.  From genes to drugs: targeted strategies for melanoma.

Authors:  Keith T Flaherty; F Stephen Hodi; David E Fisher
Journal:  Nat Rev Cancer       Date:  2012-04-05       Impact factor: 60.716

5.  Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.

Authors:  Z Dembic; K Schenck; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

6.  Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.

Authors:  Yukai He; Jiying Zhang; Cara Donahue; Louis D Falo
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

7.  Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.

Authors:  Wen-Fang Cheng; Chien-Nan Lee; Yi-Ning Su; Ming-Cheng Chang; Wen-Chun Hsiao; Chi-An Chen; Chang-Yao Hsieh
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 8.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

9.  Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Authors:  S Hong; H Li; J Qian; J Yang; Y Lu; Q Yi
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

10.  Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation.

Authors:  M Saurwein-Teissl; K Zisterer; T L Schmitt; R Glück; S Cryz; B Grubeck-Loebenstein
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.